Table 6.
Disease | Etiologic Pathogen | Geographic Regions | Vector or Exposure | Incubation Period | Presentation | Diagnosis | Management |
---|---|---|---|---|---|---|---|
Avian bird flu | H5N1 and H7N9 influenza A virus | East and Southeast Asia | Poultry | 2–8 d | Fever, malaise, myalgia, headache, nasal congestion, cough, acute respiratory distress syndrome (ARDS) | RT-PCR | Supportive care |
Diphtheria | Corynebacterium diphtheriae | Asia, South Pacific, Middle East, Eastern Europe, Caribbean | Person-to-person (oral or respiratory droplets), fomites | 2–5 d | Fever, dysphagia, malaise, anorexia, pseudomembranes | Bacterial culture | Supportive care, equine diphtheria antitoxin (DAT), antimicrobial therapy (erythromycin, penicillin) |
Coccidioidomycosis | Coccidioides immitis and Coccidioides posadasii | Central and South America | Inhalation of spores from soil | 7–21 d | Fever, malaise, cough, headache, night sweats, myalgias, arthritis, rash | Culture, IgM and IgG ELISA, immunodiffusion and complement fixation | Supportive care, antimicrobial therapy if ill or at high risk of dissemination (amphotericin B, azoles) |
Histoplasmosis | Histoplasma capsulatum | Worldwide, especially river valleys | Inhalation of spores from soil, bird droppings, bat guano | 3–17 d | Fever, headache, cough, pleuritic chest pain, malaise | Culture, microscopic examination, PCR, EIA on serum or other samples, immunodiffusion complement fixation | Supportive care, antimicrobial therapy (azole for mild to moderate disease, amphotericin B for severe) |
Legionellosis (Legionnaire’s disease and Pontiac fever) | Legionella species | Worldwide | Inhalation of freshwater aerosol | 2–10 d | Fever, headache, myalgias, pneumonia, respiratory distress | Urine antigen assay, paired serologies, PCR | Antimicrobial therapy (fluoroquinolones, macrolides) |
Melioidosis | Burkholderia pseudomallei | Central and Southeast Asia, northern Australia, South America | Subcutaneous inoculation, inhalation, ingestion; body fluids | 1–21 d | Fever, cough, weight loss, pneumonia | Culture, indirect hemagglutination assay | Antimicrobial therapy (ceftazidime, meropenem) |
Middle Eastern Respiratory Syndrome (MERS) | MERS coronavirus | North Africa, Middle East | Dromedary camel, person-to-person | 2–14 d | Fever, cough, arthralgia, diarrhea, myalgia, acute respiratory failure, multiple organ dysfunction | RT-PCR | Supportive care |
Pertussis (whooping cough) | Bordetella pertussis | Worldwide | Person-to-person (aerosolized respiratory droplets, respiratory secretions) | 7–10 d | Paroxysmal cough, post-tussive vomiting, apnea in infants | Culture, serologies, PCR | Antimicrobial therapy (macrolides) |
Adapted from Centers for Disease Control and Prevention. The yellow book: health information for international travel 2018. Philadelphia: Oxford University Press; 2017. p. 704. Available at: https://wwwnc.cdc.gov/travel/page/yellowbook-home. Accessed July 25, 2017; with permission